Stipend and Dates

Up to $12,650.

NOTE: The first group is filled before patients are placed in the next group. Group 2 Group 3
Day -1 Admit Oct 17, 2023 Oct 23, 2023
Day 5 Discharge AM Oct 22, 2023 Oct 28, 2023
Day 5 Outpatient visit 108 hr PK - PM visit Oct 22 Oct 28
Day 6 AM / PM Outpatient visit Oct 23 Oct 29
Day 7 AM / PM Outpatient visit Oct 24 Oct 30
Day 8 Outpatient visit Oct 25 Oct 31
Day 10 Outpatient visit Oct 27 Nov 02
Day 15 Outpatient visit Nov 01 Nov 07
Day 22 Outpatient visit Nov 08 Nov14
Day 29 Outpatient visit Nov 15 Nov 21
Day 36 Outpatient visit Nov 22 Nov 28
Day 43 Outpatient visit Nov 29 Dec 05
Day 50 Outpatient visit Dec 06 Dec 12
Day 57 Outpatient visit Dec 13 Dec 19
Day 71 Outpatient visit Dec 27 Jan 02, 2024
Day 85 End of study visit Jan 10, 2024 Jan 16
     
Immunogenicity Follow-up IF APPLICABLE    
Day 180 Apr 14 Apr 20
Day 270 Jul 13 Jul 19
Day 360 Oct 11 Oct 17

 

Click here to make an appointment for study DR 0737-0017

Or call 210-225-5437 for more information

 

Study Criteria

Healthy Males

Age 18-50

BMI: 18.5-30

 

Study Information

Indication: The investigational drug is being developed as a possible treatment for rheumatoid arthritis

Route of Administration: Subcutaneous

Washout from previous study: participation in an investigational clinical, surgical, drug or device study within the past 30 days prior to dosing or participated in more than 4 studies of experimental drug products in the past 12 months.

Subjects or their female partner (if they are women of childbearing potential) must be willing to use at least 1 highly effective method of contraception as described below from the time of study drug administration until 3 months after dosing. Subjects should also refrain from sperm donation during the period from the time of study drug administration until 3 months after dosing.

Highly effective birth control measures:

Subject:

  • Permanently sterile by bilateral orchidectomy
  • Sexual abstinence

For the female partner of a male subject:

  • Combined (estrogen & progestogen containing) hormonal contraception associated with inhibition of ovulation – oral, intravaginal, and transdermal;
  • Progesterone-only hormonal contraception associated with inhibition of ovulation – oral, injectable, implantable;
  • Intrauterine device;
  • Intrauterine hormone-releasing system;
  • Bilateral tubal occlusion;
  • Vasectomized partner;
  • Sexual abstinence

           

Study Reminders

  • 8 hours fasting is required for lab work (only water is allowed)
  • If taking medications, bring them to your screening appointment
  • Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a government issued identification card such as a driver's license, state issued ID card, or passport.  You will be required to show this same photo ID at all study visits
  • Arrive 30 minutes before your appointment to complete paper work.
Reference
DR 0737-0017
Name
Healthy Males Only
Gender
Male
Payment amount
Up to $12,650
Age
18 - 50
Smoking
Non-smokers